Phathom Pharmaceuticals Shares Fall After Q3 Loss Widens

MT Newswires Live11-07

Phathom Pharmaceuticals' (PHAT) shares were down 3.3% in recent Thursday trading after the company reported a Q3 net loss of $1.05 per diluted share, wider than a loss of $0.54 a year earlier.

Two analysts polled by Capital IQ projected a loss of $1.47 per share.

Net revenue for the quarter ended Sept. 30 was $16.4 million, with no year-ago revenue reported.

Analysts surveyed by Capital IQ expect $12.4 million.

"There were no revenues for the third quarter 2023 due to the launch of Voquezna taking place in the fourth quarter 2023," according to the company.

Phathom received approval from the US Food and Drug Administration in July for Voquezna tablets for the relief of heartburn related to non-erosive gastroesophageal reflux disease in adults.

Price: 17.41, Change: -0.59, Percent Change: -3.31

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481293132?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 23:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481293132","market":"sg","top_or_hot":-1,"title":"Phathom Pharmaceuticals Shares Fall After Q3 Loss Widens","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PHAT\">Phathom Pharmaceuticals</a>' (PHAT) shares were down 3.3% in recent Thursday trading after the company reported a Q3 net loss of $1.05 per diluted share, wider than a loss of $0.54 a year earlier.</p><p>Two analysts polled by Capital IQ projected a loss of $1.47 per share.</p><p>Net revenue for the quarter ended Sept. 30 was $16.4 million, with no year-ago revenue reported.</p><p>Analysts surveyed by Capital IQ expect $12.4 million.</p><p>\"There were no revenues for the third quarter 2023 due to the launch of Voquezna taking place in the fourth quarter 2023,\" according to the company.</p><p>Phathom received approval from the US Food and Drug Administration in July for Voquezna tablets for the relief of heartburn related to non-erosive gastroesophageal reflux disease in adults.</p><p>Price: 17.41, Change: -0.59, Percent Change: -3.31</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Phathom Pharmaceuticals Shares Fall After Q3 Loss Widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhathom Pharmaceuticals Shares Fall After Q3 Loss Widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 23:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Phathom Pharmaceuticals' (PHAT) shares were down 3.3% in recent Thursday trading after the company reported a Q3 net loss of $1.05 per diluted share, wider than a loss of $0.54 a year earlier.Two ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481293132","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481293132","pubTimestamp":1730993654,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Phathom Pharmaceuticals'  shares were down 3.3% in recent Thursday trading after the company reported a Q3 net loss of $1.05 per diluted share, wider than a loss of $0.54 a year earlier.Two analysts polled by Capital IQ projected a loss of $1.47 per share.Net revenue for the quarter ended Sept. 30 was $16.4 million, with no year-ago revenue reported.Analysts surveyed by Capital IQ expect $12.4 million.\"There were no revenues for the third quarter 2023 due to the launch of Voquezna taking place in the fourth quarter 2023,\" according to the company.Phathom received approval from the US Food and Drug Administration in July for Voquezna tablets for the relief of heartburn related to non-erosive gastroesophageal reflux disease in adults.Price: 17.41, Change: -0.59, Percent Change: -3.31","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PHAT":"Phathom Pharmaceuticals"},"translate_title":"Phathom Pharmaceuticals第三季度亏损扩大后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAT":1},"content_text":"Phathom Pharmaceuticals' (PHAT) shares were down 3.3% in recent Thursday trading after the company reported a Q3 net loss of $1.05 per diluted share, wider than a loss of $0.54 a year earlier.Two analysts polled by Capital IQ projected a loss of $1.47 per share.Net revenue for the quarter ended Sept. 30 was $16.4 million, with no year-ago revenue reported.Analysts surveyed by Capital IQ expect $12.4 million.\"There were no revenues for the third quarter 2023 due to the launch of Voquezna taking place in the fourth quarter 2023,\" according to the company.Phathom received approval from the US Food and Drug Administration in July for Voquezna tablets for the relief of heartburn related to non-erosive gastroesophageal reflux disease in adults.Price: 17.41, Change: -0.59, Percent Change: -3.31","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481293132"}